drugset / Trial / NCT05220072

Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156

NCT05220072 ↗

Phase 1 Completed 6 enrolled Bial R&D Investments, S.A.
NaSingle-groupOpen-labelTreatment

Summary

The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into blood cells, provide additional safety and tolerability information and collect samples for metabolite profiling and structural identification.

Timeline

Start
2021-08-28
Primary completion
2021-10-16
Completion
2021-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject BIA 28-6156 Unknown 3.7 mbq Oral
Subject BIA 28-6156 Unknown 60 mg Oral

Indications